March 3, 2020ACS Infectious Diseases354 citationsOpen Access
View Full PaperBroad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
Key Result
Niclosamide, an FDA-approved anthelminthic drug, exhibits broad antiviral activity against various viruses with nanomolar to micromolar potency, indicating potential for treating COVID-19.
Structured PICO
Does niclosamide have potential as an antiviral agent for the treatment of COVID-19 and other viral infections?
P
Population
Viral infections including SARS-CoV, MERS-CoV, ZIKV, HCV, human adenovirus, and COVID-19
I
Intervention
Niclosamide
O
Outcome
Antiviral activity
Niclosamide demonstrates broad-spectrum antiviral activity and may have potential clinical use in the treatment of COVID-19.
Abstract
The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.
Cite This Study
Xu et al. (Tue,) conducted a review in Viral infections (including COVID-19). Niclosamide was evaluated. Niclosamide, an FDA-approved anthelminthic drug, exhibits broad antiviral activity against various viruses with nanomolar to micromolar potency, indicating potential for treating COVID-19.